Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gandotinib||LY2784544||JAK2 Inhibitor - ATP competitive 15||Gandotinib (LY2784544) is an ATP-competitive inhibitor of JAK2, including JAK2 V617F, which decreases downstream signaling and may reduce cell proliferation (PMID: 23584399).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK2 V617F||myeloproliferative neoplasm||predicted - sensitive||Gandotinib||Phase I||Actionable||In a Phase I trial, treatment with Gandotinib (LY2784544) demonstrated safety in myeloproliferative neoplasm patients harboring JAK2 V617F and resulted in clinical improvement as best response in 29% (9/31) patients with myelofibrosis (PMID: 28934680).||28934680|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|